血中性粒细胞/淋巴细胞比率与相关肝脏疾病预后关系的研究进展

李乔; 郭宏华

doi:10.3969/j.issn.1001-5256.2017.04.041

血中性粒细胞/淋巴细胞比率与相关肝脏疾病预后关系的研究进展

DOI: 10.3969/j.issn.1001-5256.2017.04.041

李乔,
郭宏华

吉林大学中日联谊医院消化内科

基金项目:

吉林省科技项目资助(20140311092YY)；

详细信息

中图分类号: R575
计量
- 文章访问数: 1586
- HTML全文浏览量: 9
- PDF下载量: 376
- 被引次数: 0
出版历程
- 收稿日期: 2016-11-15
- 出版日期: 2017-04-20

Research advances in association between blood neutrophil/lymphocyte ratio and prognosis of related liver diseases

Department of Gastroenterology, China-Japan Union Hospital of Jilin University

Research funding:

摘要

摘要: 近期研究发现炎症反应与肝硬化、慢加急性肝衰竭、原发性肝癌的病情进展呈正相关并影响其预后,而中性粒细胞/淋巴细胞比率(NLR)作为炎症反应的标志物,计算简便、可重复性好,对判断其预后有良好前景。介绍了NLR与肝硬化、慢加急性肝衰竭、原发性肝癌预后的相关研究进展,认为NLR对肝硬化、慢加急性肝衰竭及原发性肝癌的预后判断有重要意义,但对于不同疾病最佳截点的选取仍存在争议,尚需进一步研究。
- 肝硬化 /
- 肝功能衰竭 /
- 肝肿瘤 /
- 中性白细胞 /
- 淋巴细胞 /
- 综述
Abstract: Recent studies have found that inflammatory response is positively associated with the progression of liver cirrhosis, acute-on-chronic liver failure, and primary liver cancer and can affect their prognosis, and as a marker for inflammatory response, neutrophil/lymphocyte ratio ( NLR) is easy to calculate, has good repeatability, and holds promise for prognostic evaluation. This article introduces the research advances in the association of NLR with the prognosis of liver cirrhosis, acute-on-chronic liver failure, and primary liver cancer and points out that NLR plays an important role in evaluating the prognosis of liver cirrhosis, acute-on-chronic liver failure, and primary liver cancer. However, there are still controversies over the selection of optimal cut-off values for different diseases, and further studies are needed.
- liver cirrhosis /
- liver failure /
- liver neoplasms /
- neutrophils /
- lymphocytes /
- review

HTML全文

参考文献(44)

[1]BIYIK M, UCAR R, SOLAK Y, et al.Blood neutrophil-to-lymphocyte ratio independently predicts survival in patients with liver cirrhosis[J].Eur J Gastroenterol Hepatol, 2013, 25 (4) :435-441.

[2]ZHANG H, SUN Q, MAO W, et al.Neutrophil-to-lymphocyte ratio predicts early mortality in patients with HBV-related decompensated cirrhosis[J].Gastroenterol Res Pract, 2016, 2016:4394650.

[3]LEITHEAD JA, RAJORIYA N, GUNSON BK, et al.Neutrophilto-lymphocyte ratio predicts mortality in patients listed for liver transplantation[J].Liver Int, 2015, 35 (2) :502-509.

[4]CHEN L, LOU Y, CHEN Y, et al.Prognostic value of the neutrophil-to-lymphocyte ratio in patients with acute-on-chronic liver failure[J].Int J Clin Pract, 2014, 68 (8) :1034-1040.

[5]DIRCHWOLF M, RUF AE.Role of systemic inflammation in cirrhosis from pathogenesis to prognosis[J].World J Hepatol, 2015, 7 (16) :1974-1981.

[6]CLRIA J, STAUBER RE, COENRAAD MJ, et al.Systemic inflammation in decompensated cirrhosis:characterization and role in acute-on-chronic liver failure[J].Hepatology, 2016, 64 (4) :1249-1264.

[7]LIU H, ZHANG H, WAN G, et al.Neutrophil-lymphocyte ratio:a novel predictor for short-term prognosis in acute-on-chronic hepatitis B liver failure[J].J Viral Hepat, 2014, 21 (7) :499-507.

[8]IMTIAZ F, SHAFIQUE K, MIRZA SS, et al.Neutrophil lymphocyte ratio as a measure of systemic inflammation in prevalent chronic diseases in Asian population[J].Int Arch Med, 2012, 5 (1) :2.

[9]XU R, HUANG H, ZHANG Z, et al.The role of neutrophils in the development of liver diseases[J].Cell Mol Immunol, 2014, 11 (3) :224-231.

[10]JAESCHKE H.Mechanisms of Liver Injury.II.Mechanisms of neutrophil-induced liver cell injury during hepatic ischemiareperfusion and other acute inflammatory conditions[J].Am J Physiol Gastrointest Liver Physiol, 2006, 290 (6) :g1083-g1088.

[11]GUNGOR G, ATASEVEN H, DEMIR A, et al.Neutrophil gelatinase-associated lipocalin in prediction of mortality in patients with hepatorenal syndrome:a prospective observational study[J].Liver Int, 2014, 34 (1) :49-57.

[12]ZOU Z, XU D, LI B, et al.Compartmentalization and its implication for peripheral immunologically-competent cells to the liver in patients with HBV-related acute-on-chronic liver failure[J].Hepatol Res, 2009, 39 (12) :1198-1207.

[13]MOREAU R, JALAN R, GINES P, et al.Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis[J].Gastroenterology, 2013, 144 (7) :1426-1437, 1437.e1-9.

[14]AGIASOTELLI D, ALEXOPOULOU A, VASILIEVA L, et al.Evaluation of neutrophil/leukocyte ratio and organ failure score as predictors of reversibility and survival following an acute-on-chronic liver failure event[J].Hepatol Res, 2016, 46 (6) :514-520.

[15]LIN BY, ZHOU L, GENG L, et al.High neutrophil-lymphocyte ratio indicates poor prognosis for acute-on-chronic liver failure after liver transplantation[J].World J Gastroenterol, 2015, 21 (11) :3317-3324.

[16]MARQUES PE, AMARAL SS, PIRES DA, et al.Chemokines and mitochondrial products activate neutrophils to amplify organ injury during mouse acute liver failure[J].Hepatology, 2012, 56 (5) :1971-1982.

[17]ARROYO V, GARCA-MARTINEZ R, SALVATELLA X.Human serum albumin, systemic inflammation, and cirrhosis[J].J Hepatol, 2014, 61 (2) :396-407.

[18]JALAN R, GINES P, OLSON JC, et al.Acute-on chronic liver failure[J].J Hepatol, 2012, 57 (6) :1336-1348.

[19]ARROYO V, MOREAU R, JALAN R, et al.Acute-on-chronic liver failure:a new syndrome that will re-classify cirrhosis[J].J Hepatol, 2015, 62 (1 Suppl) :s131-s143.

[20]ASRANI SK, O'LEARY JG.Acute-on-chronic liver failure[J].Clin Liver Dis, 2014, 18 (3) :561-574.

[21]JALAN R, PAVESI M, SALIBA F, et al.The CLIF Consortium Acute Decompensation score (CLIF-CADs) for prognosis of hospitalised cirrhotic patients without acute-on-chronic liver failure[J].J Hepatol, 2015, 62 (4) :831-840.

[22]BLASCO-ALGORA S, MASEGOSA-ATAZ J, GUTIRREZGARCA ML, et al.Acute-on-chronic liver failure:Pathogenesis, prognostic factors and management[J].World J Gastroenterol, 2015, 21 (42) :12125-12140.

[23]LIU H, HAN T, TIAN J, et al.Monitoring oxidative stress in acute-on-chronic liver failure by advanced oxidation protein products[J].Hepatol Res, 2012, 42 (2) :171-180.

[24]FU SJ, SHEN SL, LI SQ, et al.Prognostic value of preoperative peripheral neutrophil-to-lymphocyte ratio in patients with HBVassociated hepatocellular carcinoma after radical hepatectomy[J].Med Oncol, 2013, 30 (4) :721.

[25]MCNALLY ME, MARTINEZ A, KHABIRI H, et al.Inflammatory markers are associated with outcome in patients with unresectable hepatocellular carcinoma undergoing transarterial chemoembolization[J].Ann Surg Oncol, 2013, 20 (3) :923-928.

[26]WANG WJ, ZHAO Y, XIA DD, et al.Predictive value of neutrophil-lymphocyte ratio and its dynamic change in patients with hepatocellular carcinoma undergoing transarterial chemoembolization[J].J Clin Hepatol, 2016, 32 (6) :1139-1144. (in Chinese) 王文军, 赵艳, 夏冬东, 等.中性粒细胞与淋巴细胞比值及其动态变化对经肝动脉化疗栓塞术治疗的肝细胞癌患者预后的预测价值[J].临床肝胆病杂志, 2016, 32 (6) :1139-1144.

[27]MOTOMURA T, SHIRABE K, MANO Y, et al.Neutrophil-lymphocyte ratio reflects hepatocellular carcinoma recurrence after liver transplantation via inflammatory microenvironment[J].J Hepatol, 2013, 58 (1) :58-64.

[28]DAN J, ZHANG Y, PENG Z, et al.Postoperative neutrophil-tolymphocyte ratio change predicts survival of patients with small hepatocellular carcinoma undergoing radiofrequency ablation[J].PLo S One, 2013, 8 (3) :e58184.

[29]WANG XB, GAO FY, LIU Y.Neutrophil-lymphocyte ratio:a novel predictor of clinical outcome of patients with hepatocellular carcinoma[J].J Clin Hepatol, 2016, 32 (4) :649-652. (in Chinese) 王宪波, 高方媛, 刘尧.中性粒细胞与淋巴细胞比值:一项评价肝细胞癌患者预后的新指标[J].临床肝胆病杂志, 2016, 32 (4) :649-652.

[30]COUSSENS LM, WERB Z.Inflammation and cancer[J].Nature, 2002, 420 (6917) :860-867.

[31]MALLAPPA S, SINHA A, GUPTA S, et al.Preoperative neutrophil to lymphocyte ratio>5 is a prognostic factor for recurrent colorectal cancer[J].Colorectal Dis, 2013, 15 (3) :323-328.

[32]SULLIVAN KM, GROESCHL RT, TURAGA KK, et al.Neutrophil-to-lymphocyte ratio as a predictor of outcomes for patients with hepatocellular carcinoma:a Western perspective[J].J Surg Oncol, 2014, 109 (2) :95-97.

[33]OH BS, JANG JW, KWON JH, et al.Prognostic value of C-reactive protein and neutrophil-to-lymphocyte ratio in patients with hepatocellular carcinoma[J].BMC Cancer, 2013, 13:78.

[34]MISHALIAN I, BAYUH R, LEVY L, et al.Tumor-associated neutrophils (TAN) develop pro-tumorigenic[J].Cancer Immunol Immunother, 2013, 62 (11) :1745-1756.

[35]SUZUKI K, KACHALA SS, KADOTA K, et al.Prognostic immune markers in non-small cell lung cancer[J].Clin Cancer Res, 2011, 17 (16) :5247-5256.

[36]ZHANG TT, BAI L.Progress on the relationship between hepatocellular carcinoma and chronic inflammation[J].Chin Clin Oncol, 2014, 19 (8) :752-758. (in Chinese) 张婷婷, 白莉.肝细胞癌和慢性炎症相互关系的研究进展[J].临床肿瘤学杂志, 2014, 19 (8) :752-758.

[37]PERISANIDIS C, KORNEK G, PSCHL PW, et al.High neutrophil-to-lymphocyte ratio is an independent marker of poor disease-specific survival in patients with oral cancer[J].Med Oncol, 2013, 30 (1) :334.

[38]POLLARD JW.Tumour-educated macrophages promote tumour progression and metastasis[J].Nat Rev Cancer, 2004, 4 (1) :71-78.

[39]YI YX, WANG J, ZHANG T, et al.Study on detection and clinical significance of CD33+HLA-DR-MDSCs cells in hepatocellular carcinoma[J].Chin J Immunol, 2015, 31 (11) :1520-1523. (in Chinese) 易永祥, 王建, 张彤, 等.肝细胞癌患者外周血CD33+HLADR-MDSCs的监测及其临床意义[J].中国免疫学杂志, 2015, 31 (11) :1520-1523.

[40]LIN X, LI W, LAI J, et al.Five-year update on the mouse model of orthotopic lung transplantation:scientific uses, tricks of the trade, and tips for success[J].J Thorac Dis, 2012, 4 (3) :247-258.

[41]SHIBUTANI M, MAEDA K, NAGAHARA H, et al.A high preoperative neutrophil-to-lymphocyte ratio is associated with poor survival in patients with colorectal cancer[J].Anticancer Res, 2013, 33 (8) :3291-3294.

[42]PILLAY J, KAMP VM, van HOFFEN E, et al.A subset of neutrophils in human systemic inflammation inhibits T cell responses through Mac-1[J].J Clin Invest, 2012, 122 (1) :327-336.

[43]MA Y, XU YC, TANG L, et al.Cytokine-induced killer (CIK) cell therapy for patients with hepatocellular carcinoma:efficacy and safety[J].Exp Hematol Oncol, 2012, 1 (1) :11.

[44]KEIZMAN D, ISH-SHALOM M, HUANG P, et al.The association of pre-treatment neutrophil to lymphocyte ratio with response rate, progression free survival and overall survival of patients treated with sunitinib for metastatic renal cell carcinoma[J].Eur J Cancer, 2012, 48 (2) :202-208.

施引文献

资源附件(0)

访问统计